EHRA 2023: Late-Breaking Science Video Collection

Published: 18 April 2023

  • Views:

    Views Icon 1766
  • Likes:

    Heart Icon 7
Average (ratings)
No ratings
Your rating

Overview

For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research and clinical practice. 

About the episode

EHRA 23 - Dr Marco Bergonti (Istituto Cardiocentro Ticino, CH) to discuss the key takeaways from the ANTWOORD II Trial. 

In this study, 605 heart failure patients undergoing atrial fibrillation ablation were enrolled to receive an ANTWERP Score, which aimed to predict LVEF recovery. 70% of patients were categorised as 'responders', patients identified as those who could benefit the most from AF ablation. 

Results suggest that responders to the study achieved 10 times less deaths and heart transplantations, 10 times less heart failure hospitalisations and 8 times more positive left ventricular remodeling. 

Questions:

  1. Can you provide a brief overview of the ANTWOORD I trial and explain the research question that ANTWOORD II aims to address?
  2. Could you elaborate on the ANTWERP scoring system and how it is used in the study?
  3. Can you describe the study design, entry criteria, and patient population in detail?
  4. What were the main findings of the study and what conclusions can be drawn from them?
  5. What are the clinical implications of the study?
  6. What are some limitations of the study that should be considered?
  7. What are the next steps?

Recorded from EHRA 2023, Barcelona.

Faculty Biographies

Marco Bergonti

View full profile

Comments

You must be to comment. If you are not registered, you can register here.